Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H12N2O |
Molecular Weight | 236.2686 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)N1C2=C(C=CC=C2)C=CC3=C1C=CC=C3
InChI
InChIKey=FFGPTBGBLSHEPO-UHFFFAOYSA-N
InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
Molecular Formula | C15H12N2O |
Molecular Weight | 236.2686 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/016608s097,018281s045,018927s038,020234s026lbl.pdfCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/carbamazepine.html
http://www.rxlist.com/carnexiv-drug.htm
http://www.wikidoc.org/index.php/Carbamazepine
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/016608s097,018281s045,018927s038,020234s026lbl.pdf
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/carbamazepine.html
http://www.rxlist.com/carnexiv-drug.htm
http://www.wikidoc.org/index.php/Carbamazepine
Carbamazepine is an analgesic, anti-epileptic agent that is FDA approved for the treatment of epilepsy, trigeminal neuralgia. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. It depresses thalamic potential and bulbar and polysynaptic reflexes, including the linguomandibular reflex in cats. Commonly reported side effects of carbamazepine include: dizziness, drowsiness, nausea, ataxia, and vomiting. Carbamazepine is a potent inducer of hepatic CYP1A2, 2B6, 2C9/19, and 3A4 and may reduce plasma concentrations of concomitant medications mainly metabolized by CYP1A2, 2B6, 2C9/19, and 3A4 through induction of their metabolism, like Boceprevir, Cyclophosphamide, Aripiprazole, Tacrolimus, Temsirolimus and others.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q14524|||E9PFW7 Gene ID: 6331.0 Gene Symbol: SCN5A Target Organism: Homo sapiens (Human) |
152.0 µM [IC50] | ||
Target ID: Q99250 Gene ID: 6326.0 Gene Symbol: SCN2A Target Organism: Homo sapiens (Human) |
25.0 µM [Ki] | ||
Target ID: Q9NY46|||Q9Y6P4 Gene ID: 6328.0 Gene Symbol: SCN3A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17381447 |
16.0 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TEGRETOL Approved UseEpilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. Launch Date1968 |
|||
Primary | TEGRETOL Approved UseEpilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. Launch Date1968 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.2 μg/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARBAMAZEPINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FASTED |
|
1.9 μg/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARBAMAZEPINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
11 μg/mL |
800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CARBAMAZEPINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4.3 μg/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARBAMAZEPINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: HIGH-FAT |
|
3.2 μg/mL |
1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CARBAMAZEPINE-10,11-EPOXIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
1.5 μg/mL |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CARBAMAZEPINE-10,11-EPOXIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
0.11 μg/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARBAMAZEPINE-10,11-EPOXIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
2.2 μg/mL |
800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CARBAMAZEPINE-10,11-EPOXIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
32.6 μg × h/mL |
1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CARBAMAZEPINE-10,11-EPOXIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
15.7 μg × h/mL |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CARBAMAZEPINE-10,11-EPOXIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
37.5 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARBAMAZEPINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
14.5 h |
800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CARBAMAZEPINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
34 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARBAMAZEPINE-10,11-EPOXIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24% |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARBAMAZEPINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
50% |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARBAMAZEPINE-10,11-EPOXIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: Page: p.1297 |
unhealthy, 73.1 ± 5.5 n = 91 Health Status: unhealthy Condition: Epilepsy Age Group: 73.1 ± 5.5 Sex: M+F Population Size: 91 Sources: Page: p.1297 |
Disc. AE: Skin and subcutaneous conditions NEC, Fatigue... AEs leading to discontinuation/dose reduction: Skin and subcutaneous conditions NEC (8.8%) Sources: Page: p.1297Fatigue Somnolence |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Skin and subcutaneous conditions NEC | 8.8% Disc. AE |
1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: Page: p.1297 |
unhealthy, 73.1 ± 5.5 n = 91 Health Status: unhealthy Condition: Epilepsy Age Group: 73.1 ± 5.5 Sex: M+F Population Size: 91 Sources: Page: p.1297 |
Fatigue | Disc. AE | 1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: Page: p.1297 |
unhealthy, 73.1 ± 5.5 n = 91 Health Status: unhealthy Condition: Epilepsy Age Group: 73.1 ± 5.5 Sex: M+F Population Size: 91 Sources: Page: p.1297 |
Somnolence | Disc. AE | 1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: Page: p.1297 |
unhealthy, 73.1 ± 5.5 n = 91 Health Status: unhealthy Condition: Epilepsy Age Group: 73.1 ± 5.5 Sex: M+F Population Size: 91 Sources: Page: p.1297 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
strong | yes (co-administration study) Comment: Midazolam plasma concentrations reduced dramatically in patients treated with carbamazepine and phenytoin; The CYP3A4-mediated metabolism of cyclosporin is markedly accelerated by carbamazepine comedication; Many other likely DDIs with carbamazepine. See https://pubmed.ncbi.nlm.nih.gov/8877250/ Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016608s115_018281_s058_018927s055_020234_s047.pdf@page=10 Page: 12.0 |
|||
Page: 12.0 |
yes | |||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/29158009/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/29158009/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: A 2- to 4-fold increase in serum carbamazepine concentrations has been reported in patients given troleandomycin or erythromycin (CYP3A4 inhibitors); Many other likely DDIs with carbamazepine. See https://pubmed.ncbi.nlm.nih.gov/8877250/ Page: 12.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/17584909/ Page: 6.0 |
PubMed
Title | Date | PubMed |
---|---|---|
New developments in the pharmacotherapy of alcohol dependence. | 2001 |
|
Update on anticonvulsants for the treatment of alcohol withdrawal. | 2001 |
|
Investigation and medical management of trigeminal neuralgia by consultant oral and maxillofacial surgeons in the British Isles. | 2001 Apr |
|
Novel treatments for bipolar disorder. | 2001 Apr |
|
Comparison the cognitive effect of anti-epileptic drugs in seizure-free children with epilepsy before and after drug withdrawal. | 2001 Apr |
|
Mood and behavioural disorders following traumatic brain injury: clinical evaluation and pharmacological management. | 2001 Feb |
|
Determination of the antiepileptics vigabatrin and gabapentin in dosage forms and biological fluids using Hantzsch reaction. | 2001 Feb |
|
Illness characteristics and their association with prescription patterns for bipolar I disorder. | 2001 Feb |
|
Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. | 2001 Feb |
|
Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin. | 2001 Feb |
|
Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring. | 2001 Feb |
|
Functional changes and adverse reactions after successful treatment of hereditary myokymia: a case report. | 2001 Feb |
|
Recommendations for the management of behavioral and psychological symptoms of dementia. | 2001 Feb |
|
Interactions between carbamazepine and polyethylene glycol (PEG) 6000: characterisations of the physical, solid dispersed and eutectic mixtures. | 2001 Feb |
|
Glutamate receptor antagonists differentially affect the protective activity of conventional antiepileptics against amygdala-kindled seizures in rats. | 2001 Feb |
|
Prolonged epileptic blindness in an infant associated with cortical dysplasia. | 2001 Feb |
|
Anticonvulsant and sodium channel blocking activity of higher doses of clenbuterol. | 2001 Feb |
|
The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation. | 2001 Feb |
|
Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population. | 2001 Feb |
|
Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. | 2001 Feb |
|
Pleomorphic xanthoastrocytoma: report of a case diagnosed by intraoperative cytopathological examination. | 2001 Feb |
|
Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. | 2001 Feb |
|
Significance of atypical presentation of symptomatic SUNCT: a case report. | 2001 Feb |
|
The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. | 2001 Feb |
|
Independent short-term variability of spike-like (600 Hz) and postsynaptic (N20) cerebral SEP components. | 2001 Feb 12 |
|
A model of atypical absence seizures: EEG, pharmacology, and developmental characterization. | 2001 Feb 13 |
|
[Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics]. | 2001 Feb 17 |
|
[Febrile convulsions, Treatment and prognosis]. | 2001 Feb 19 |
|
Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry. | 2001 Feb 23 |
|
[Carbamazepine-induced SIADH with clinical signs of delirium]. | 2001 Jan |
|
Seizures in multiple sclerosis. | 2001 Jan |
|
Carbamazepine hypersensitivity syndrome mimicking mycosis fungoides. | 2001 Jan |
|
Relief of cluster headache and cranial neuralgias. Promising prophylactic and symptomatic treatments. | 2001 Jan |
|
Ritonavir-induced carbamazepine toxicity. | 2001 Jan |
|
Acute intermittent porphyria, seizures, and antiepileptic drugs: a report on a 3-year-old Nigerian boy. | 2001 Jan |
|
[Klüver-Bucy syndrome in herpetic meningoencephalitis]. | 2001 Jan 27 |
|
Changes in color vision after a single dose of vigabatrin or carbamazepine in healthy volunteers. | 2001 Jan-Feb |
|
Mood stabilizers and ion regulation. | 2001 Jan-Feb |
|
Taking the sting out of trigeminal neuralgia. | 2001 Mar |
|
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants. | 2001 Mar |
|
Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. | 2001 Mar |
|
Treatment of bipolar affective disorder in clinical practice. | 2001 Mar |
|
Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. | 2001 Mar |
|
Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. | 2001 Mar |
|
Suppressive effects of oxcarbazepine on tooth pulp-evoked potentials recorded at the trigeminal spinal tract nucleus in cats. | 2001 Mar |
|
The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities. | 2001 Mar 14 |
|
Carbamazepine prevents imipramine-induced behavioural sensitization to the dopamine D(2)-like receptor agonist quinpirole. | 2001 Mar 23 |
|
Separation of olanzapine, carbamazepine and their main metabolites by capillary electrophoresis with pseudo-stationary phases. | 2001 Mar 5 |
|
Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. | 2001 Mar 7 |
|
New anticonvulsants for use in pediatric patients (part I). | 2001 Mar-Apr |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/016608s097,018281s045,018927s038,020234s026lbl.pdf http://www.rxlist.com/carnexiv-drug/indications-dosage.htm
Curator's Comment: The total daily dose of CARNEXIV is 70% of the total daily oral carbamazepine dose from which patients are being switched. The total daily dose of CARNEXIV should be equally divided in four 30-minute infusions, separated by 6 hours.
Initial Dose: 400 mg per day.
Subsequent Dose: add up to 200 mg per day at weekly intervals.
Maximum daily dose is 1600 mg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12386121
Human liver microsomes (HLMs) converted carbamazepine (30-300 microM) to 3-hydroxycarbamazepine at rates >25 times those of 2-hydroxycarbamazepine. Rates of carbamazepine 2- and 3-hydroxylation correlated strongly with CYP2B6 activity (r >or= 0.757) in a panel of HLMs (n = 8). Carbamazepine 3-hydroxylation also correlated significantly with CYP2C8 activity at a carbamazepine concentration of 30 microM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:38:29 GMT 2023
by
admin
on
Sat Dec 16 17:38:29 GMT 2023
|
Record UNII |
33CM23913M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C264
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
NDF-RT |
N0000008486
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
NDF-RT |
N0000175753
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
24.2.2
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
NDF-RT |
N0000175751
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
43590
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
265508
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
WHO-ATC |
N03AF01
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
LIVERTOX |
NBK548097
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
WHO-VATC |
QN03AF01
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/16/1746
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
05
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB06113MIG
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
Carbamazepine
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
169864
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
DTXSID4022731
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
298-46-4
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
3019
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
206-062-7
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
33CM23913M
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
CARBAMAZEPINE
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
CHEMBL108
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
33CM23913M
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
N0000191266
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | Cytochrome P450 1A2 Inducers [MoA] | ||
|
100000092127
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
2554
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
m3053
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | Merck Index | ||
|
2002
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | RxNorm | ||
|
489
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
DB00564
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
1836
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
C341
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
N0000185607
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | Cytochrome P450 2C19 Inducers [MoA] | ||
|
D002220
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
CARBAMAZEPINE
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | Description: A white to yellowish white, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water and ether R; soluble in ethanol (~750 g/l) TS. Category: Antiepileptic drug. Storage: Carbamazepine should be kept in a tightly closed container. Definition: Carbamazepine contains not less than 98.0% and not more than 102.0% of C15H12N2O, calculated with reference to the dried substance. | ||
|
N0000187064
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | Cytochrome P450 2B6 Inducers [MoA] | ||
|
3387
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
N0000185507
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | Cytochrome P450 2C9 Inducers [MoA] | ||
|
1093001
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
5339
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | |||
|
N0000185506
Created by
admin on Sat Dec 16 17:38:34 GMT 2023 , Edited by admin on Sat Dec 16 17:38:34 GMT 2023
|
PRIMARY | Cytochrome P450 3A4 Inducers [MoA] |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INDUCER | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
TARGET -> INHIBITOR |
|
||
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> INDUCER | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
METABOLIC ENZYME -> INDUCER |
POTENT
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
MINOR
URINE
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||